Please join us for the Thursday, May 11, 2006 Bioentrepreneurs Club networking
event and discussion with:
Woodruff Emlen, M.D., CEO and co-founder of Taligen Therapeutics
Taligen Therapeutics, Inc. is a biotechnology company founded by Dr. V Michael Holers and Dr. Woodruff Emlen in March 2004 to develop and commercialize technology from the University of Colorado for the treatment of inflammatory diseases. The Company is focused on developing innovative technologies to manipulate complement proteins of the immune system to inhibit inflammation and to target inhibitors of inflammation to specific sites of tissue injury.
Based on medical need, the competitive landscape and pre-clinical data, the Company is focusing on three areas of major unmet medical need: asthma, traumatic brain injury, and autoimmune disease. Taligen’s products are currently in pre-clinical development with estimated time to Phase I studies of two years.
Mr. Emlen will discuss howTaligen’s technology moved from the academic realm into biotech.
7:30–8:00 a.m. - Registration, Breakfast, and Networking
8:00–9:00 a.m. - Presentation by Woodruff Emlen, M.D.
Continental breakfast will be provided. There is no charge to attend.
Self-parking is available at the Hyatt Garage which is accessible on Glenarm between 17th & 18th. Parking will not be validated.